BeiGene
ONC
#682
Rank
โ‚ฌ25.60 B
Marketcap
225,68ย โ‚ฌ
Share price
2.82%
Change (1 day)
67.55%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (ONC)

Earnings in 2024 (TTM): -โ‚ฌ0.53 Billion

According to BeiGene 's latest financial reports the company's current earnings are โ‚ฌ3.81 Billion. , an increase over its 2023 earnings that were of -โ‚ฌ1.07 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 -โ‚ฌ0.51 Billion-52.95%
2023 -โ‚ฌ1.07 Billion-32.52%
2022 -โ‚ฌ1.58 Billion24.39%
2021 -โ‚ฌ1.27 Billion-13.21%
2020 -โ‚ฌ1.47 Billion72.69%
2019 -โ‚ฌ0.85 Billion36.01%
2018 -โ‚ฌ0.63 Billion616.83%
2017 -โ‚ฌ86.75 Million-15.24%
2016 -โ‚ฌ0.11 Billion107.91%
2015 -โ‚ฌ49.23 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚ฌ16 Million-96.80%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ9.13 Million-98.18%๐Ÿ‡บ๐Ÿ‡ธ USA